Longevity Biotech, Inc. is focused on changing the established neuroscience paradigm. Instead of concentrating on clearing plaques or relying exclusively on genetics, Longevity Biotech is developing a new approach to improve the lives of people suffering from neurodegeneration diseases. Longevity’s initial focus is Parkinson’s Disease, and it is expanding its pipeline to address other related neurodegeneration diseases. Longevity Biotech products have unique attributes which are expected to provide either first-in-class or best-in-class product profiles.
To achieve this goal, Longevity Biotech has two independent and complementary platforms which power Longevity’s product portfolio. Longevity Biotech’s Precision Neuroscience Platform™ allows us to profile the immune system and determine the ‘health’ of the single most important aspect of these autoimmune diseases. By understanding the status of patient immune systems, Longevity is developing products that ‘reset’ the immune system of these patients using on our proprietary Hybridtide™ Platform. Hybridtide™ provides a dramatically improved therapeutic and novel biological product profile to our synthetic peptide-based products.
Longevity Biotech has received significant funding support from scientifically rigorous organizations such as the Michael J. Fox Foundation, the National Multiple Sclerosis Society of the United States and Canada, the National Institutes of Health, and the National Science Foundation.
Additionally, Longevity Biotech partners with organizations around the world on various development and platform-based collaborations. Our valuable partners play a key role in our mission.